Skip to main content

Table 4 Results of Cox proportional hazard regression analyses in rEF

From: Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction

 

Univariable

Multivariable

HR

95% CI

p

HR

95% CI

p

Age: 1-year increase

1.06

1.04–1.09

 < 0.001

1.04

1.02–1.07

 < 0.001

Men: yes

0.60

0.36–1.05

0.070

0.84

0.48–1.55

0.556

Hypertension: yes

0.89

0.58–1.38

0.595

   

Diabetes Mellitus: yes

0.74

0.49–1.11

0.145

   

CKD (eGFR < 60 mL/min/1.73m2): yes

2.83

1.83–4.46

 < 0.001

1.72

1.05–2.86

0.030

Family History of IHD: yes

0.93

0.57–1.47

0.759

   

Current smoking: yes

0.71

0.40–1.19

0.199

   

LDL-C: 1 mg/dL increase

1.00

0.99–1.00

0.589

   

HDL-C: 1 mg/dL increase

1.01

0.99–1.02

0.536

   

LVEF: 1% increase

0.97

0.94–0.99

0.034

0.98

0.95–1.01

0.118

Multivessel disease: yes

1.47

0.92–2.43

0.108

   

Acute Coronary Syndrome: yes

1.90

1.26–2.91

0.002

1.61

1.02–2.54

0.041

Statins use: yes

0.55

0.35–0.84

0.005

1.01

0.62–1.65

0.953

ACEIs/ARBs use: yes

0.43

0.28–0.64

 < 0.001

0.59

0.37–0.95

0.029

Aspirin use: yes

0.53

0.32–0.95

0.034

0.66

0.37–1.25

0.194

Beta blocker use: yes

0.53

0.34–0.81

0.003

0.59

0.36–0.97

0.036

  1. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CI confidence interval, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, HR hazard ratio, IHD ischemic heart disease, LDL-C low-density lipoprotein cholesterol, LVEF left ventricular ejection fraction; mrEF, mid-range ejection fraction
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us